ANL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast ANL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANL is USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 0.000

Low

9.00

Averages

High

9.00

Current: 0.000

Low

9.00

Averages

High

9.00

H.C. Wainwright

Buy -> Neutral

downgrade

2025-06-02

Reason

H.C. Wainwright

Price Target

2025-06-02

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Adlai Nortye to Neutral from Buy.

H.C. Wainwright

Joseph Pantginis

Buy -> Neutral

downgrade

2025-06-02

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

2025-06-02

downgrade

Buy -> Neutral

Reason

H.C. Wainwright analyst Joseph Pantginis downgraded Adlai Nortye to Neutral from Buy and removing its prior $9 price target on the shares after the company recently announced that the Phase 3 BURAN trial evaluating its lead asset buparlisib in combination with paclitaxel for the treatment of advanced HNSCC did not meet the primary endpoint of improving overall survival compared to paclitaxel alone. With these "disappointing" results and the "unfortunate" pivotal miss, the company has decided to discontinue advancement of the buparlisib program and intends to refocus resources on the advancement of two preclinical assets, AN8025 and AN9025, the analyst noted. Given the early stage nature of the remainder of the Adlai pipeline, the firm is downgrading shares as it awaits future clinical updates, the analyst explains.

Valuation Metrics

The current forward P/E ratio for Adlai Nortye Ltd (ANL.O) is -3.83, compared to its 5-year average forward P/E of -4.27. For a more detailed relative valuation and DCF analysis to assess Adlai Nortye Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.27

Current PE

-3.83

Overvalued PE

-2.18

Undervalued PE

-6.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.19

Current EV/EBITDA

-1.34

Overvalued EV/EBITDA

1.40

Undervalued EV/EBITDA

-3.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.21

Current PS

0.00

Overvalued PS

4.99

Undervalued PS

-4.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ANL News & Events

Events Timeline

No data

News

4.5

01-02Benzinga

Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%

8.5

2025-12-30Benzinga

Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%

3.5

2025-12-29Newsfilter

Xeriant Launches Factor X R&D Group Targeting $1.8 Trillion Green Construction Market

People Also Watch

Frequently Asked Questions

What is Adlai Nortye Ltd (ANL) stock price today?

The current price of ANL is 1.55 USD — it has increased 5.44 % in the last trading day.

What is Adlai Nortye Ltd (ANL)'s business?

Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.

What is the price predicton of ANL Stock?

Wall Street analysts forecast ANL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANL is USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Adlai Nortye Ltd (ANL)'s revenue for the last quarter?

Adlai Nortye Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Adlai Nortye Ltd (ANL)'s earnings per share (EPS) for the last quarter?

Adlai Nortye Ltd. EPS for the last quarter amounts to -0.57 USD, decreased % YoY.

What changes have occurred in the market's expectations for Adlai Nortye Ltd (ANL)'s fundamentals?

The market is revising No Change the revenue expectations for Adlai Nortye Ltd. (ANL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -8.82%.

How many employees does Adlai Nortye Ltd (ANL). have?

Adlai Nortye Ltd (ANL) has 123 emplpoyees as of January 09 2026.

What is Adlai Nortye Ltd (ANL) market cap?

Today ANL has the market capitalization of 54.24M USD.